Controversies and Challenges in Defining the Etiology and Pathophysiology of Restless Legs Syndrome

American Journal of Medicine

Volumn 120, Issue 1 SUPPL. 1, 2007, Pages

  Allen, Richard P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Epidemiology; Iron; Restless Legs Syndrome

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE; IRON; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE EXACERBATION; FAMILY STUDY; GENETICS; HUMAN; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME;

CENTRAL NERVOUS SYSTEM; DOPAMINE; HUMANS; IRON; PHENOTYPE; PREVALENCE; RESTLESS LEGS SYNDROME;

EID: 33845792112     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.11.003     Document Type: Article

References (44)

1. Allen R.P., and Earley C.J. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med 1 (2000) 11-19
2. Earley C.J., Barker P.B., Horská A., and Allen R.P. MRI-determined regional brain iron concentrations in early and late-onset restless legs syndrome. Sleep Med. 7 (2006) 459-461
3. Connor J.R., Boyer P.J., Menzies S.L., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 61 (2003) 304-309
4. Hening W., Walters A.S., Allen R.P., et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5 (2004) 237-246
5. Allen R.P., Picchietti D., Hening W.A., et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the Restless Legs Syndrome Diagnosis and Epidemiology Workshop at the National Institutes of Health. Sleep Med 4 (2003) 101-119
6. Rothdach A.J., Trenkwalder C., Haberstock J., Keil U., and Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO [Memory and Morbidity in Augsburg Elderly] study. Neurology 54 (2000) 1064-1068
7. Berger K., Luedemann J., Trenkwalder C., John U., and Kessler C. Sex and risk of restless legs syndrome in the general population. Arch Intern Med 164 (2004) 196-202
8. Allen R.P., Walters A.S., Montplaisir J., et al. Restless legs syndrome prevalence and impact. Arch Intern Med 165 (2005) 1286-1292
9. Nichols D.A., Kushida C.A., Allen R.P., et al. Validation of RLS diagnostic questions in a primary care practice. [abstract]. Sleep 26 (2003) A346
10. Sevim S., Dogu O., Camdeviren H., et al. Unexpected low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 61 (2003) 1562-1569
11. Allen R.P., and Earley C.J. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 18 (2001) 128-147
12. Milligan S.A., and Chesson A.L. Restless legs syndrome in the older adult: diagnosis and management. Drugs Aging 19 (2002) 741-751
13. Kushida C.A. Clinical presentation, diagnosis, and quality of life issues in restless legs syndrome. Am J Med. 120 suppl 1A (2007) 4-12
14. Allen R.P., LaBuda M.C., Beckert P., and Earley C.J. Family history study of the restless legs syndrome. Sleep Med 3 suppl (2002) S3-S7
15. Winkelmann J., Muller-Myhosok B., Wittchen H., et al. Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age onset families. Ann Neurol 52 (2002) 297-302
16. Desautels A., Turecki G., Montplaisir J., et al. Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 69 (2001) 1266-1270
17. Bonati M.T., Ferini-Strambi L., Aridon P., et al. Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 126 (2003) 1485-1492
18. Chen S., Ondo W.G., Rao S., et al. Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 74 (2004) 876-885
19. Hening W.A., Allen R.P., Earley C.J., et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27 (2004) 560-583
20. Allen R. Dopamine and iron in the pathophysiology of restless legs syndrome (RLS). Sleep Med 5 (2004) 385-391
21. Earley C.J., Allen R.P., Beard J.L., and Connor J.R. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 62 (2000) 623-628
22. Garcia-Borreguero D., Larrosa O., Granizo J.J., de la Llave Y., and Hening W.A. Circadian variation in neuroendocrine response to l-dopa in patients with restless legs syndrome. Sleep 27 (2004) 669-673
23. O'Keeffe S.T., Gavin K., and Lavan J.N. Iron status and restless legs syndrome in the elderly. Age Ageing 23 (1994) 200-203
24. Bara-Jimenez W., Aksu M., Graham B., Sato S., and Hallett M. Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology 54 (2000) 1609-1615
25. Bucher S.F., Seelos K.C., Oertel W.H., Reiser M., and Trenkwalder C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 41 (1997) 639-645
26. Hokfelt T., Phillipson O., and Goldstein M. Evidence for a dopaminergic pathway in the rat descending from the A11 cell group to the spinal cord. Acta Physiol Scand 107 (1979) 393-395
27. Skagerberg G., Bjorklund A., Lindvall O., and Schmidt R.H. Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 9 (1982) 237-244
28. Fleetwood-Walker S.M., Hope P.J., Mitchell R., el-Yassir N., and Molony V. The influence of opioid receptor subtypes on the processing of nociceptive inputs in the spinal dorsal horn of the cat. Brain Res 451 (1988) 213-226
29. Ondo W.G., He Y., Rajasekaran S., and Le W.D. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 15 (2000) 154-158
30. 18F-dopa and 11C-raclopride PET studies. Neurology 52 (1999) 932-937
31. Ruottinen H.M., Partinen M., Hublin C., et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 54 (2000) 502-504
32. Eisensehr I., Wetter T.C., Linke R., et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 57 (2001) 1307-1309
33. Tribl G.G., Asenbaum S., Klosch G., et al. Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome. Neurology 59 (2002) 649-650
34. Michaud M., Soucy J.P., Chabli A., Lavigne G., and Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 249 (2002) 164-170
35. Earley C.J., Connor J.R., Beard J.L., et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54 (2000) 1698-1700
36. Mizuno S., Mihara T., Miyaoka T., Inagaki T., and Horiguchi J. CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 14 (2005) 43-47
37. Allen R.P., Barker P.B., Wehrl F., Song H.K., and Earley C.J. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56 (2001) 263-265
38. Schmidauer C., Sojer M., Seppi K., et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 58 (2005) 630-634
39. Sun E.R., Chen C.A., Ho G., Earley C.J., and Allen R.P. Iron and the restless legs syndrome. Sleep 21 (1998) 371-377
40. 2 receptors in rat brain. Pharmacol Biochem Behav 69 (2001) 409-418
41. Wang X., Wiesinger J., Beard J., et al. Thy1 expression in the brain is affected by iron and is decreased in restless legs syndrome. J Neurosci 220 (2004) 59-66
42. Connor J.R., Wang X.S., Patton S.M., et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 62 (2004) 1563-1567
43. Allen R.P., and Earley C.J. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19 (1996) 205-213
44. Happe S., and Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 18 (2004) 27-36